X-Linked Hypophosphataemia Epiomic Epidemiology Report - Forecast In 20 Major Markets 2018-2028 - ResearchAndMarkets.com

DUBLIN--()--The "Epiomic Epidemiology Series: X-Linked Hypophosphataemia Forecast In 20 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

X-linked hypophosphataemia (XLH) is the most common inherited form of hypophosphataemic rickets, a diverse group of inherited disorders involving impaired bone mineralisation due to hypophosphataemia, which leads to bone weakness and deformities, bowed limbs, reduced growth, bone pain and associated disorders. Even though current therapy can improve the signs of rickets and biochemical parameters, the disease constitutes a serious burden and negatively affects the quality of life of the patients, causing serious morbidity at adult age.

This report provides the current prevalent population for XLH across 20 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Austria, Russia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Some features of XLH patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of XLH include:

  • Insufficiency fractures
  • Osteoarthritis
  • Enthesopathy
  • Dental disease
  • Tertiary hyperparathyroidism (treatment-related)
  • Hearing impairment
  • Optic atrophy
  • Nephrocalcinosis

Key Topics Covered:

1. List Of Tables And Figures

2. Introduction

3. Cause Of The Disease

4. Risk Factors & Prevention

5. Diagnosis Of The Disease

6. Variation By Geography/Ethnicity

7. Disease Prognosis & Clinical Course

8. Key Comorbid Conditions / Features Associated With The Disease

9. Methodology For Quantification Of Patient Numbers

10. Top-Line Prevalence For X-Linked Hypophosphataemia

11. Features Of X-Linked Hypophosphataemia Patients

12. Comorbidities Of X-Linked Hypophosphataemia Patients

13. Abbreviations Used In The Report

14. Reports & Publications

15. Online Epidemiology Databases

16. Online Pharmaceutical Pricing Database

17. References

18. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/f96tjj/xlinked?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900